Search research articles
Contact Us
Filters
Showing results (191-200 of 426) with videos related to
Page
of 43
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2013
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
Stephen Harland, John Staffurth, Arturo Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2013
First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors
André T Brunetto, Joo Ern Ang, Rohit Lal, et al.
European Urology
|
November 24, 2018
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial
Kate L Mahon, Wenjia Qu, Hui-Ming Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors
Johann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L R Molife, G Attard, P C Fong, et al.
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy
Crescens Tiu, Rajiv Shinde, Abhijit Pal, et al.
Gene Therapy
|
March 8, 2008
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial
C L White, K R Twigger, L Vidal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2011
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
J S de Bono, L R Molife, G Sonpavde, et al.
BJU International
|
February 3, 2015
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)
Amit Bahl, Susan Masson, Zafar Malik, et al.
Oncogene
|
June 24, 2023
Critical role of antioxidant programs in enzalutamide-resistant prostate cancer
Eliot B Blatt, Karla Parra, Antje Neeb, et al.
Page
of 43
Search research articles
Search
Showing results (191-200 of 426) with videos related to
Sort By:
Page
of 43
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2013
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
Stephen Harland, John Staffurth, Arturo Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2013
First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors
André T Brunetto, Joo Ern Ang, Rohit Lal, et al.
European Urology
|
November 24, 2018
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial
Kate L Mahon, Wenjia Qu, Hui-Ming Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors
Johann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L R Molife, G Attard, P C Fong, et al.
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy
Crescens Tiu, Rajiv Shinde, Abhijit Pal, et al.
Gene Therapy
|
March 8, 2008
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial
C L White, K R Twigger, L Vidal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2011
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
J S de Bono, L R Molife, G Sonpavde, et al.
BJU International
|
February 3, 2015
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)
Amit Bahl, Susan Masson, Zafar Malik, et al.
Oncogene
|
June 24, 2023
Critical role of antioxidant programs in enzalutamide-resistant prostate cancer
Eliot B Blatt, Karla Parra, Antje Neeb, et al.
Page
of 43